It is not bringing down US prices, but delaying launches in Europe. Reuters reports:
Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous 10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer.
You can read the full article here.
